Sana Biotechnology acquires Oscine

By The Science Advisory Board staff writers

November 2, 2020 -- Sana Biotechnology, a developer of engineered cellular medicines, has acquired Oscine under terms that were not disclosed.

Oscine's glial progenitor cell program and underlying technologies will be integrated with Sana's broader platform and programs. Glial progenitor cells differentiate into the major support cells of the central nervous system (CNS): oligodendrocytes and astrocytes. These cells have the potential to treat not only myelin disorders, but a broad array of neurodegenerative and neuropsychiatric diseases.

Oscine's scientific founder Dr. Steve Goldman, PhD, joins Sana as the head of CNS therapy. During his 30-year career, he has worked at the University of Rochester as professor and chairman of the neurology department, and as chief of its division of cell and gene therapy. He also serves as co-director of Rochester's Center for Translational Neuromedicine.

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter